James Andrew McCubrey

List of Publications by Year
in descending order

347 papers	20,437 citations	12303 69 h-index	14702 127 g-index
348 all docs	348 docs citations	348 times ranked	28985 citing authors

#	Article	IF	Citations
1	Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochimica Et Biophysica Acta - Molecular Cell Research, 2007, 1773, 1263-1284.	1.9	1,858
2	Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell, 2006, 10, 375-388.	7.7	921
3	Reactive Oxygen Species-Induced Activation of the MAP Kinase Signaling Pathways. Antioxidants and Redox Signaling, 2006, 8, 1775-1789.	2.5	685
4	Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Advances in Enzyme Regulation, 2006, 46, 249-279.	2.9	584
5	Transfer of specificity by murine Î± and Î² T-cell receptor genes. Nature, 1986, 320, 232-238.	13.7	583
6	Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging, 2011, 3, 192-222.	1.4	520
7	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health. Oncotarget, 2011, 2, 135-164.	0.8	509
8	GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget, 2014, 5, 2881-2911.	0.8	407
9	Senescence-Associated Exosome Release from Human Prostate Cancer Cells. Cancer Research, 2008, 68, 7864-7871.	0.4	391
10	Use of an aqueous soluble tetrazolium/formazan assay to measure viability and proliferation of lymphokine-dependent cell lines. Journal of Immunological Methods, 1993, 157, 233-240.	0.6	306
11	Cutaneous melanoma: From pathogenesis to therapy (Review). International Journal of Oncology, 2018, 52, 1071-1080.	1.4	281
12	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance. Oncotarget, 2012, 3, 1068-1111.	0.8	279
13	Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response.. Oncotarget, 2012, 3, 954-987.	0.8	244
14	Current treatment strategies for inhibiting mTOR in cancer. Trends in Pharmacological Sciences, 2015, 36, 124-135.	4.0	234
15	Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. Oncotarget, 2014, 5, 4603-4650.	0.8	231
16	The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget, 2010, 1, 89-103.	0.8	227
17	Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia, 2008, 22, 708-722.	3.3	222
18	PIK3CA mutations in human solid tumors: Role in sensitivity to various therapeutic approaches. Cell Cycle, 2009, 8, 1352-1358.	1.3	173

#	Article	IF	Citations
19	Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs. Aging, 2017, 9, 1477-1536.	1.4	168
20	Phosphatidylinositol 3â€²-Kinase Activation Leads to Multidrug Resistance Protein-1 Expression and Subsequent Chemoresistance in Advanced Prostate Cancer Cells. Cancer Research, 2004, 64, 8397-8404.	0.4	154
21	Activity of the Novel Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 against T-Cell Acute Lymphoblastic Leukemia. Cancer Research, 2010, 70, 8097-8107.	0.4	152
22	Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget, 2012, 3, 236-260.	0.8	152
23	Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. Journal of Cellular Physiology, 2011, 226, 2762-2781.	2.0	147
24	Targeting GSK3 and Associated Signaling Pathways Involved in Cancer. Cells, 2020, 9, 1110.	1.8	146
25	Effects of mutations in Wnt/Î²-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activityâ€”Diverse effects on cell growth, metabolism and cancer. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 2942-2976.	1.9	137
26	Molecular mechanisms of sorafenib action in liver cancer cells. Cell Cycle, 2012, 11, 2843-2855.	1.3	129
27	Akt as a therapeutic target in cancer. Expert Opinion on Therapeutic Targets, 2008, 12, 1139-1165.	1.5	125
28	Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells. Advances in Biological Regulation, 2015, 59, 65-81.	1.4	121
29	A Novel Ring-Substituted Diindolylmethane,1,1-Bis[3â€²-(5-Methoxyindolyl)]-1-(p-t-Butylphenyl) Methane, Inhibits Extracellular Signal-Regulated Kinase Activation and Induces Apoptosis in Acute Myelogenous Leukemia. Cancer Research, 2005, 65, 2890-2898.	0.4	116
30	Dual Inhibition of Class IA Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin as a New Therapeutic Option for T-Cell Acute Lymphoblastic Leukemia. Cancer Research, 2009, 69, 3520-3528.	0.4	116
31	Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review). International Journal of Oncology, 2003, 22, 469-80.	1.4	116
32	Redox Regulation of the Calcium/Calmodulin-dependent Protein Kinases. Journal of Biological Chemistry, 2004, 279, 44573-44581.	1.6	114
33	PLC and PI3K/Akt/mTOR signalling in disease and cancer. Advances in Biological Regulation, 2015, 57, 10-16.	1.4	111
34	The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle, 2010, 9, 1781-1791.	1.3	110
35	Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. Oncotarget, 2012, 3, 371-394.	0.8	109
36	The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. Biochimica Et Biophysica Acta - Molecular Cell Research, 2010, 1803, 991-1002.	1.9	106

#	Article	IF	Citations
37	Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. Expert Opinion on Investigational Drugs, 2009, 18, 1333-1349.	1.9	104
38	Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 449-463.	1.9	104
39	Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis. Advances in Biological Regulation, 2015, 57, 75-101.	1.4	100
40	Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells. Oncogene, 2003, 22, 2478-2492.	2.6	95
41	The therapeutic potential of mTOR inhibitors in breast cancer. British Journal of Clinical Pharmacology, 2016, 82, 1189-1212.	1.1	93
42	Analysis of BRAF Mutation in Primary and Metastatic Melanoma. Cell Cycle, 2005, 4, 1382-1384.	1.3	91
43	p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3. Cell Cycle, 2012, 11, 4579-4588.	1.3	91
44	Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer. Oncotarget, 2014, 5, 1576-1594.	0.8	91
45	mTOR as a multifunctional therapeutic target in HIV infection. Drug Discovery Today, 2011, 16, 715-721.	3.2	90
46	The complexity of PTEN: mutation, marker and potential target for therapeutic intervention. Expert Opinion on Therapeutic Targets, 2004, 8, 537-550.	1.5	89
47	Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle, 2008, 7, 1745-1762.	1.3	89
48	A Dominant Role for p53-Dependent Cellular Senescence in Radiosensitization of Human Prostate Cancer Cells. Cell Cycle, 2007, 6, 595-605.	1.3	87
49	The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors. , 2000, 88, 229-279.		86
50	Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells. Oncotarget, 2017, 8, 14221-14250.	0.8	86
51	Synergistic Proapoptotic Activity of Recombinant TRAIL Plus the Akt Inhibitor Perifosine in Acute Myelogenous Leukemia Cells. Cancer Research, 2008, 68, 9394-9403.	0.4	84
52	Pancreatic cancer stem cells: Association with cell surface markers, prognosis, resistance, metastasis and treatment. Advances in Biological Regulation, 2014, 56, 45-50.	1.4	83
53	Targeting GSK3 signaling as a potential therapy of neurodegenerative diseases and aging. Expert Opinion on Therapeutic Targets, 2018, 22, 833-848.	1.5	83
54	Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance. Clinical Cancer Research, 2003, 9, 1161-70.	3.2	82

#	Article	IF	Citations
55	Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (Review). International Journal of Oncology, 2012, 40, 639-44.	1.4	81
56	Solubility and Bioactivity of the Pseudomonas Quinolone Signal Are Increased by a Pseudomonas aeruginosa-Produced Surfactant. Infection and Immunity, 2005, 73, 878-882.	1.0	80
57	Calcium/Calmodulin-Dependent Kinase I and Calcium/Calmodulin-Dependent Kinase Kinase Participate in the Control of Cell Cycle Progression in MCF-7 Human Breast Cancer Cells. Cancer Research, 2005, 65, 5408-5416.	0.4	80
58	Diverse roles of GSK-3: Tumor promoterâ€“tumor suppressor, target in cancer therapy. Advances in Biological Regulation, 2014, 54, 176-196.	1.4	80
59	Roles of NGAL and MMP-9 in the tumor microenvironment and sensitivity to targeted therapy. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 438-448.	1.9	79
60	Targeting the RAF/MEK/ERK, PI3K/AKT and P53 pathways in hematopoietic drug resistance. Advances in Enzyme Regulation, 2007, 47, 64-103.	2.9	77
61	Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. Cell Cycle, 2011, 10, 3003-3015.	1.3	77
62	A conditionally-active form of MEK1 results in autocrine transformation of human and mouse hematopoietic cells. Oncogene, 2000, 19, 526-536.	2.6	76
63	Preclinical evaluation of the PI3K/Akt/mTOR pathway in animal models of multiple sclerosis. Oncotarget, 2018, 9, 8263-8277.	0.8	75
64	Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resistance Updates, 2007, 10, 81-100.	6.5	74
65	Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs. Prostate, 2009, 69, 1448-1459.	1.2	74
66	Autophagy in acute leukemias: A double-edged sword with important therapeutic implications. Biochimica Et Biophysica Acta - Molecular Cell Research, 2015, 1853, 14-26.	1.9	74
67	Computational identification of microRNAs associated to both epithelial to mesenchymal transition and NGAL/MMP-9 pathways in bladder cancer. Oncotarget, 2016, 7, 72758-72766.	0.8	73
68	Involvement of Akt-1 and mTOR in Sensitivity of Breast Cancer to Targeted Therapy. Oncotarget, 2011, 2, 538-550.	0.8	73
69	Oleocanthal exerts antitumor effects on human liver and colon cancer cells through ROS generation. International Journal of Oncology, 2017, 51, 533-544.	1.4	72
70	Impact of physical exercise in cancer survivors during and after antineoplastic treatments. Oncotarget, 2018, 9, 14005-14034.	0.8	71
71	Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance. Leukemia, 2008, 22, 2080-2090.	3.3	70
72	Potential use of rapamycin in HIV infection. British Journal of Clinical Pharmacology, 2010, 70, 784-793.	1.1	67

#	Article	IF	Citations
73	MMP-9 overexpression is associated with intragenic hypermethylation of MMP9 gene in melanoma. Aging, 2016, 8, 933-944.	1.4	67
74	Drug discovery targeting the mTOR pathway. Clinical Science, 2018, 132, 543-568.	1.8	65
75	Melanoma: Molecular pathogenesis and emerging target therapies (Review). International Journal of Oncology, 2009, 34, 1481-9.	1.4	64
76	HIVâ€protease inhibitors for the treatment of cancer: Repositioning HIV protease inhibitors while developing more potent NOâ€hybridized derivatives?. International Journal of Cancer, 2017, 140, 1713-1726.	2.3	63
77	EGF Induces Cell Motility and Multi-Drug Resistance Gene Expression in Breast Cancer Cells. Cell Cycle, 2006, 5, 2820-2826.	1.3	62
78	Synergy between PI3K/Akt and Raf/MEK/ERK Pathways in IGF-1R Mediated Cell Cycle Progression and Prevention of Apoptosis in Hematopoietic Cells. Cell Cycle, 2004, 3, 370-377.	1.3	60
79	Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation. Oncotarget, 2014, 5, 10034-10047.	0.8	60
80	Preclinical testing of the Akt inhibitor triciribine in Tâ€cell acute lymphoblastic leukemia. Journal of Cellular Physiology, 2011, 226, 822-831.	2.0	59
81	RAS/RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1 and TP53 pathways and regulatory miRs as therapeutic targets in hepatocellular carcinoma. Expert Opinion on Therapeutic Targets, 2019, 23, 915-929.	1.5	59
82	EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review). International Journal of Oncology, 2003, 22, 237-52.	1.4	59
83	NOTCH3 expression is linked to breast cancer seeding and distant metastasis. Breast Cancer Research, 2018, 20, 105.	2.2	58
84	Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels. Oncotarget, 2012, 3, 811-823.	0.8	58
85	Calcium-induced ERK activation in human T lymphocytes occurs via p56Lck and CaM-kinase. Molecular Immunology, 2000, 37, 675-683.	1.0	56
86	Signaling Intermediates (MAPK and PI3K) as Therapeutic Targets in NSCLC. Current Pharmaceutical Design, 2014, 20, 3944-3957.	0.9	55
87	Participation of the Calcium/Calmodulin-dependent Kinases in Hydrogen Peroxide-induced IÎºB Phosphorylation in Human T Lymphocytes. Journal of Biological Chemistry, 2002, 277, 30469-30476.	1.6	54
88	Emerging MEK inhibitors. Expert Opinion on Emerging Drugs, 2010, 15, 203-223.	1.0	54
89	The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. Journal of Molecular Medicine, 2012, 90, 667-679.	1.7	54
90	A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. Oncotarget, 2012, 3, 1615-1628.	0.8	54

#	Article	IF	Citations
91	Cardiovascular disease-related miRNAs expression: potential role as biomarkers and effects of training exercise. Oncotarget, 2018, 9, 17238-17254.	0.8	51
92	The Role of GSK-3 in Cancer Immunotherapy: GSK-3 Inhibitors as a New Frontier in Cancer Treatment. Cells, 2020, 9, 1427.	1.8	51
93	Computational Modeling of PI3K/AKT and MAPK Signaling Pathways in Melanoma Cancer. PLoS ONE, 2016, 11, e0152104.	1.1	50
94	Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. Current Opinion in Investigational Drugs, 2008, 9, 614-30.	2.3	50
95	EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review). International Journal of Oncology, 2003, 22, 237.	1.4	49
96	Integrin signaling links protein kinase CÉ› to the protein kinase B/Akt survival pathway in recurrent prostate cancer cells. Oncogene, 2004, 23, 8659-8672.	2.6	49
97	Nuclear Phosphatidylinositol Signaling: Focus on Phosphatidylinositol Phosphate Kinases and Phospholipases C. Journal of Cellular Physiology, 2016, 231, 1645-1655.	2.0	48
98	Insulin Receptor Substrate Is a Mediator of Phosphoinositide 3-Kinase Activation in Quiescent Pancreatic Cancer Cells. Cancer Research, 2005, 65, 9164-9168.	0.4	47
99	The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: whatâ€™s genetics got to do with it?. Expert Opinion on Therapeutic Targets, 2005, 9, 1009-1030.	1.5	47
100	Activation of the Calcium/Calmodulin-Dependent Protein Kinases as a Consequence of Oxidative Stress. Antioxidants and Redox Signaling, 2006, 8, 1807-1817.	2.5	47
101	In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells. Cell Cycle, 2011, 10, 492-499.	1.3	47
102	The AKT Inhibitor MK-2206 is Cytotoxic in Hepatocarcinoma Cells Displaying Hyperphosphorylated AKT-1 and Synergizes with Conventional Chemotherapy. Oncotarget, 2013, 4, 1496-1506.	0.8	47
103	Antitumor Effects of Dehydroxymethylepoxyquinomicin, a Novel Nuclear Factor-ÎºB Inhibitor, in Human Liver Cancer Cells Are Mediated through a Reactive Oxygen Species-Dependent Mechanism. Molecular Pharmacology, 2009, 76, 290-300.	1.0	46
104	P21Cip1 induced by Raf is associated with increased Cdk4 activity in hematopoietic cells. Oncogene, 2001, 20, 4354-4364.	2.6	45
105	PKR Regulates B56Î±-mediated BCL2 Phosphatase Activity in Acute Lymphoblastic Leukemia-derived REH Cells. Journal of Biological Chemistry, 2008, 283, 35474-35485.	1.6	45
106	Inhibition of Cdk2 kinase activity selectively targets the CD44+/CD24â^'/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells. International Journal of Oncology, 2014, 45, 1193-1199.	1.4	45
107	Metformin influences drug sensitivity in pancreatic cancer cells. Advances in Biological Regulation, 2018, 68, 13-30.	1.4	45
108	The PI3K/Akt/mTOR pathway: A potential pharmacological target in COVID-19. Drug Discovery Today, 2022, 27, 848-856.	3.2	45

#	Article	IF	Citations
109	B-Rafâ€“dependent expression of vascular endothelial growth factorâ€“A in Kaposi sarcomaâ€“associated herpesvirus-infected human B cells. Blood, 2005, 105, 4516-4522.	0.6	44
110	Increased Protein Expression of the PTEN Tumor Suppressor in the Presence of Constitutively Active Notch-1. Cell Cycle, 2005, 4, 1389-1395.	1.3	44
111	Analysis of the B-RAFV600E mutation in cutaneous melanoma patients with occupational sun exposure. Oncology Reports, 2014, 31, 1079-1082.	1.2	44
112	PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. Scientific Reports, 2017, 7, 43013.	1.6	44
113	The mechanism of contribution of integrin linked kinase (ILK) to epithelial-mesenchymal transition (EMT). Advances in Enzyme Regulation, 2011, 51, 195-207.	2.9	43
114	Activity of the selective IÎºB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia. Cell Cycle, 2012, 11, 2467-2475.	1.3	43
115	The Role of Downstream Signaling Pathways of the Epidermal Growth Factor Receptor for Artesunates Activity in Cancer Cells. Current Cancer Drug Targets, 2009, 9, 72-80.	0.8	42
116	NOTCH and PTEN in prostate cancer. Advances in Biological Regulation, 2014, 56, 51-65.	1.4	42
117	Influence of physical exercise on microRNAs in skeletal muscle regeneration, aging and diseases. Oncotarget, 2018, 9, 17220-17237.	0.8	42
118	Molecular Pathways Leading to Oxidative Stress-Induced Phosphorylation of Akt. Antioxidants and Redox Signaling, 2006, 8, 1749-1756.	2.5	41
119	Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells. Advances in Enzyme Regulation, 2010, 50, 285-307.	2.9	41
120	Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs. Cell Cycle, 2010, 9, 1629-1638.	1.3	41
121	Inhibition of GSK-3Î² activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in MCF-7 breast cancer cells. Cell Cycle, 2014, 13, 820-833.	1.3	41
122	Cooperative Effects of Akt-1 and Raf-1 on the Induction of Cellular Senescence in Doxorubicin or Tamoxifen Treated Breast Cancer Cells. Oncotarget, 2011, 2, 610-626.	0.8	41
123	Advances in Targeting Signal Transduction Pathways. Oncotarget, 2012, 3, 1505-1521.	0.8	41
124	Raf promotes human herpesvirus-8 (HHV-8/KSHV) infection. Oncogene, 2004, 23, 5227-5241.	2.6	40
125	The Emerging Role of the Phosphatidylinositol 3-Kinase/ Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cell Biology. Cancers, 2010, 2, 1576-1596.	1.7	40
126	PI3K activation is associated with intracellular sodium/iodide symporter protein expression in breast cancer. BMC Cancer, 2007, 7, 137.	1.1	39

#	Article	IF	Citations
127	Novel combination of Celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor cells. Cell Cycle, 2010, 9, 1399-1410.	1.3	39
128	Targeting the Cancer Initiating Cell: The Ultimate Target for Cancer Therapy. Current Pharmaceutical Design, 2012, 18, 1784-1795.	0.9	39
129	Emerging targeted therapies for melanoma treatment (Review). International Journal of Oncology, 2014, 45, 516-524.	1.4	39
130	Pivotal roles of glycogen synthase-3 in hepatocellular carcinoma. Advances in Biological Regulation, 2017, 65, 59-76.	1.4	39
131	Regulation of GSK-3 activity by curcumin, berberine and resveratrol: Potential effects on multiple diseases. Advances in Biological Regulation, 2017, 65, 77-88.	1.4	39
132	Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-Î¹B. Oncotarget, 2016, 7, 1323-1340.	0.8	39
133	The antitumor properties of a nontoxic, nitric oxideâ€“modified version of saquinavir are independent of Akt. Molecular Cancer Therapeutics, 2009, 8, 1169-1178.	1.9	38
134	K562 cell proliferation is modulated by PLCÎ²1 through a PKCÎ±-mediated pathway. Cell Cycle, 2013, 12, 1713-1721.	1.3	38
135	Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies. Expert Opinion on Therapeutic Targets, 2012, 16, 729-742.	1.5	37
136	New landscapes and horizons in hepatocellular carcinoma therapy. Aging, 2020, 12, 3053-3094.	1.4	37
137	Calcium/calmodulin-dependent protein kinases as potential targets in cancer therapy. Expert Opinion on Therapeutic Targets, 2005, 9, 791-808.	1.5	36
138	Roles of TP53 in determining therapeutic sensitivity, growth, cellular senescence, invasion and metastasis. Advances in Biological Regulation, 2017, 63, 32-48.	1.4	36
139	Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma. International Journal of Cancer, 2019, 144, 2613-2624.	2.3	36
140	Assessment of the effect of sphingosine kinase inhibitors on apoptosis,unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics. Oncotarget, 2014, 5, 7886-7901.	0.8	36
141	Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia. Oncotarget, 2015, 6, 32089-32103.	0.8	36
142	Genetic interactions in induction of endogenous murine leukemia virus from low leukemic mice. Cell, 1982, 28, 881-888.	13.5	35
143	Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for â€œverticalâ€•and â€œlateralâ€•combination strategies. Journal of Molecular Medicine, 2012, 90, 1133-1144.	1.7	35
144	Novel roles of androgen receptor, epidermal growth factor receptor, TP53, regulatory RNAs, NF-kappa-B, chromosomal translocations, neutrophil associated gelatinase, and matrix metalloproteinase-9 in prostate cancer and prostate cancer stem cells. Advances in Biological Regulation, 2016, 60, 64-87.	1.4	35

#	Article	IF	Citations
145	Targeting the phosphatidylinositol 3â€kinase/Akt/mechanistic target of rapamycin signaling pathway in Bâ€lineage acute lymphoblastic leukemia: An update. Journal of Cellular Physiology, 2018, 233, 6440-6454.	2.0	35
146	Detection ofBRAFgene mutation in primary choroidal melanoma tissue. Cancer Biology and Therapy, 2006, 5, 225-227.	1.5	34
147	Akt inactivates ERK causing decreased response to chemotherapeutic drugs in advanced CaP cells. Cell Cycle, 2008, 7, 631-636.	1.3	34
148	Characterization of human melanoma cell lines and melanocytes by proteome analysis. Cell Cycle, 2011, 10, 2924-2936.	1.3	34
149	Novel Combination of Sorafenib and Celecoxib Provides Synergistic Anti-Proliferative and Pro-Apoptotic Effects in Human Liver Cancer Cells. PLoS ONE, 2013, 8, e65569.	1.1	34
150	PLC-Î²1 and cell differentiation: An insight into myogenesis and osteogenesis. Advances in Biological Regulation, 2017, 63, 1-5.	1.4	34
151	Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update. International Journal of Molecular Sciences, 2018, 19, 1878.	1.8	34
152	Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells. Advances in Biological Regulation, 2019, 71, 172-182.	1.4	34
153	Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy. Current Pharmaceutical Design, 2016, 22, 2358-2388.	0.9	34
154	Proapoptotic Activity and Chemosensitizing Effect of the Novel Akt Inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-amine (A443654) in T-Cell Acute Lymphoblastic Leukemia. Molecular Pharmacology, 2008, 74, 884-895.	1.0	33
155	Emerging Raf inhibitors. Expert Opinion on Emerging Drugs, 2009, 14, 633-648.	1.0	33
156	Nuclear phospholipase C Î²1 signaling, epigenetics and treatments in MDS. Advances in Biological Regulation, 2013, 53, 2-7.	1.4	32
157	Nuclear PI-PLCÎ²1: An appraisal on targets and pathology. Advances in Biological Regulation, 2014, 54, 2-11.	1.4	32
158	Targeting breast cancer initiating cells: Advances in breast cancer research and therapy. Advances in Biological Regulation, 2014, 56, 81-107.	1.4	32
159	PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors. Oncotarget, 2015, 6, 10399-10414.	0.8	32
160	A PTEN inhibitor displays preclinical activity against hepatocarcinoma cells. Cell Cycle, 2016, 15, 573-583.	1.3	31
161	Inhibition of the CaM-Kinases augments cell death in response to oxygen radicals and oxygen radical inducing cancer therapies in MCF-7 human breast cancer cells. Cancer Biology and Therapy, 2006, 5, 1022-1030.	1.5	30
162	Nuclear phosphoinositides and their roles in cell biology and disease. Critical Reviews in Biochemistry and Molecular Biology, 2011, 46, 436-457.	2.3	30

#	Article	IF	Citations
163	The novel NF-Î²B inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism. Cancer Letters, 2012, 322, 35-44.	3.2	30
164	Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia. Cell Cycle, 2014, 13, 2237-2247.	1.3	30
165	Nuclear inositide signaling and cell cycle. Advances in Biological Regulation, 2018, 67, 1-6.	1.4	30
166	The Key Roles of PTEN in T-Cell Acute Lymphoblastic Leukemia Development, Progression, and Therapeutic Response. Cancers, 2019, 11, 629.	1.7	30
167	Cancer therapy and treatments during COVID-19 era. Advances in Biological Regulation, 2020, 77, 100739.	1.4	30
168	Aurora-A Mitotic Kinase Induces Endocrine Resistance through Down-Regulation of ERÎ± Expression in Initially ERÎ±+ Breast Cancer Cells. PLoS ONE, 2014, 9, e96995.	1.1	30
169	The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling network and the control of normal myelopoiesis. Histology and Histopathology, 2010, 25, 669-80.	0.5	30
170	Cytotoxic activity of the novel small molecule AKT inhibitor SC66 in hepatocellular carcinoma cells. Oncotarget, 2015, 6, 1707-1722.	0.8	30
171	The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells. Oncotarget, 2015, 6, 17147-17160.	0.8	30
172	Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy. Cell Cycle, 2010, 9, 1839-1846.	1.3	29
173	Tumor microenvironment in diffuse large B-cell lymphoma: Matrixmetalloproteinases activation is mediated by osteopontin overexpression. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 483-489.	1.9	29
174	The Unfolded Protein Response: A Novel Therapeutic Target in Acute Leukemias. Cancers, 2020, 12, 333.	1.7	29
175	The Effects of Beta-Estradiol on Raf Activity, Cell Cycle Progression and Growth Factor Synthesis in the MCF-7 Breast Cancer Cell Line. Cancer Biology and Therapy, 2002, 1, 256-262.	1.5	28
176	Raf-Induced Cell Cycle Progression in Human TF-1 Hematopoietic Cells. Cell Cycle, 2002, 1, 218-224.	1.3	28
177	Therapeutic Potential of Nitric Oxide-Modified Drugs in Colon Cancer Cells. Molecular Pharmacology, 2012, 82, 700-710.	1.0	28
178	Nuclear Inositide Signaling Via Phospholipase C. Journal of Cellular Biochemistry, 2017, 118, 1969-1978.	1.2	28
179	Targeting the Raf kinase cascade in cancer therapy â€“ novel molecular targets and therapeutic strategies. Expert Opinion on Therapeutic Targets, 2002, 6, 659-678.	1.5	27
180	Signaling through 3â€²,5â€²-Cyclic Adenosine Monophosphate and Phosphoinositide-3 Kinase Induces Sodium/Iodide Symporter Expression in Breast Cancer. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5196-5203.	1.8	27

#	Article	IF	Citations
181	Elevated serum levels of osteopontin in HCV-associated lymphoproliferative disorders. Cancer Biology and Therapy, 2005, 4, 1192-1194.	1.5	27
182	Conditional EGFR Promotes Cell Cycle Progression and Prevention of Apoptosis in the Absence of Autocrine Cytokines. Cell Cycle, 2005, 4, 822-830.	1.3	27
183	Absence of BRAF Gene Mutation in Non-Melanoma Skin Tumors. Cell Cycle, 2006, 5, 968-970.	1.3	27
184	COX-2-Dependent and COX-2-Independent Mode of Action of Celecoxib in Human Liver Cancer Cells. OMICS A Journal of Integrative Biology, 2011, 15, 383-392.	1.0	27
185	Malignant melanoma in elderly patients: biological, surgical and medical issues. Expert Review of Anticancer Therapy, 2015, 15, 101-108.	1.1	27
186	Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals. Advances in Biological Regulation, 2018, 69, 16-34.	1.4	27
187	Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia. Oncotarget, 2015, 6, 6597-6610.	0.8	27
188	Reactive Oxygen Intermediates and Signaling Through Kinase Pathways. Antioxidants and Redox Signaling, 2006, 8, 1745-1748.	2.5	26
189	Identification of a functional nuclear export sequence in diacyl glycerol kinase-Î¶. Cell Cycle, 2010, 9, 384-388.	1.3	26
190	BRAF mutations in papillary thyroid carcinoma and emerging targeted therapies (Review). Molecular Medicine Reports, 2012, 6, 687-694.	1.1	25
191	The NO-modified HIV protease inhibitor as a valuable drug for hematological malignancies: Role of p70S6K. Leukemia Research, 2015, 39, 1088-1095.	0.4	25
192	Modulation of nuclear PI-PLCbeta1 during cell differentiation. Advances in Biological Regulation, 2016, 60, 1-5.	1.4	25
193	Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells. Advances in Biological Regulation, 2019, 73, 100633.	1.4	25
194	Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes. Leukemia, 2019, 33, 2276-2290.	3.3	25
195	Nuclear phospholipase C isoenzyme imbalance leads to pathologies in brain, hematologic, neuromuscular, and fertility disorders. Journal of Lipid Research, 2019, 60, 312-317.	2.0	25
196	Effects of deregulated RAF and MEK1 expression on the cytokine-dependency of hematopoietic cells. Advances in Enzyme Regulation, 2000, 40, 305-337.	2.9	24
197	Raf-Induced Vascular Endothelial Growth Factor Augments Kaposi's Sarcoma-Associated Herpesvirus Infection. Journal of Virology, 2004, 78, 13381-13390.	1.5	24
198	Nuclear translocation of PKCâ€•Î± is associated with cell cycle arrest and erythroid differentiation in myelodysplastic syndromes (MDSs). FASEB Journal, 2018, 32, 681-692.	0.2	24

#	Article	IF	Citations
199	Recent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes. Oncotarget, 2012, 3, 1522-1532.	0.8	24
200	Raf-1 oncogenic signaling is linked to activation of mesenchymal to epithelial transition pathway in metastatic breast cancer cells. International Journal of Oncology, 2012, 40, 1858-64.	1.4	23
201	PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: New options for targeted therapy. Advances in Biological Regulation, 2012, 52, 214-227.	1.4	23
202	Molecular targeting of the Aurora-A/SMAD5 oncogenic axis restores chemosensitivity in human breast cancer cells. Oncotarget, 2017, 8, 91803-91816.	0.8	23
203	Effects of berberine, curcumin, resveratrol alone and in combination with chemotherapeutic drugs and signal transduction inhibitors on cancer cellsâ€"Power of nutraceuticals. Advances in Biological Regulation, 2018, 67, 190-211.	1.4	23
204	Nuclear Nox4 interaction with prelamin A is associated with nuclear redox control of stem cell aging. Aging, 2018, 10, 2911-2934.	1.4	23
205	Synergistic effects of pi3k/akt on abrogation of cytokine-dependency induced by oncogenic raf. Advances in Enzyme Regulation, 2001, 41, 289-323.	2.9	22
206	Vascular endothelial growth factor augments human herpesvirus-8 (HHV-8/KSHV) infection. Cancer Biology and Therapy, 2004, 3, 876-881.	1.5	22
207	Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine. Cell Cycle, 2012, 11, 4447-4461.	1.3	22
208	Molecular Targeted Therapy in Melanoma: A Way to Reverse Resistance to Conventional Drugs. Current Drug Delivery, 2012, 9, 17-29.	0.8	22
209	Recent progress in targeting cancer. Aging, 2011, 3, 1154-1162.	1.4	22
210	Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia. Oncotarget, 2016, 7, 79842-79853.	0.8	22
211	Selective Activation of Nuclear PI-PLCbeta1 During Normal and Therapy-Related Differentiation. Current Pharmaceutical Design, 2016, 22, 2345-2348.	0.9	22
212	Selective Killing of Adriamycin-Resistant (G2 Checkpoint-Deficient and MRP1-Expressing) Cancer Cells by Docetaxel. Cancer Research, 2005, 65, 4401-4407.	0.4	21
213	Analysis of TIMP-1 Gene Polymorphisms in Italian Sclerodermic Patients. Journal of Clinical Laboratory Analysis, 2006, 20, 173-176.	0.9	21
214	Roles of p53, NF-Î¹B and the androgen receptor in controlling NGAL expression in prostate cancer cell lines. Advances in Biological Regulation, 2018, 69, 43-62.	1.4	21
215	Therapeutic resistance in breast cancer cells can result from deregulated EGFR signaling. Advances in Biological Regulation, 2020, 78, 100758.	1.4	21
216	TP53/miR-34a-associated signaling targets SERPINE1 expression in human pancreatic cancer. Aging, 2020, 12, 2777-2797.	1.4	21

#	Article	IF	Citations
217	Ability of the activated PI3K/Akt oncoproteins to synergize with MEK1 and induce cell cycle progression and abrogate the cytokine-dependence of hematopoietic cells. Cell Cycle, 2004, 3, 503-12.	1.3	21
218	Targeting the PI3K and MAPK pathways to treat Kaposiâ€™s sarcoma-associated herpes virus infection and pathogenesis. Expert Opinion on Therapeutic Targets, 2007, 11, 589-599.	1.5	20
219	Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy. Advances in Enzyme Regulation, 2008, 48, 113-135.	2.9	20
220	Revisiting nuclear phospholipase C signalling in MDS. Advances in Biological Regulation, 2012, 52, 2-6.	1.4	20
221	Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (Review). International Journal of Oncology, 2014, 45, 909-918.	1.4	20
222	Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2019, 1866, 1322-1337.	1.9	20
223	GSK-3: a multifaceted player in acute leukemias. Leukemia, 2021, 35, 1829-1842.	3.3	20
224	Effects of a conditionally active v-ErbB and an EGF-R inhibitor on transformation of NIH-3T3 cells and abrogation of cytokine dependency of hematopoietic cells. Oncogene, 2004, 23, 7810-7820.	2.6	19
225	Inhibition of Cdk2 activity decreases Aurora-A kinase centrosomal localization and prevents centrosome amplification in breast cancer cells. Oncology Reports, 2013, 29, 1785-1788.	1.2	19
226	Clusterin enhances AKT2â€mediated motility of normal and cancer prostate cells through a PTEN and PHLPP1 circuit. Journal of Cellular Physiology, 2019, 234, 11188-11199.	2.0	19
227	GSK-3Î² Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals. Cells, 2021, 10, 816.	1.8	19
228	PLC-beta 1 regulates the expression of miR-210 during mithramycin-mediated erythroid differentiation in K562 cells. Oncotarget, 2014, 5, 4222-4231.	0.8	19
229	Recent discoveries in the cycling, growing and aging of the p53 field. Aging, 2012, 4, 887-893.	1.4	18
230	The Reverse Warburg Effect Is Associated with Fbp2-Dependent Hif1Î± Regulation in Cancer Cells Stimulated by Fibroblasts. Cells, 2020, 9, 205.	1.8	18
231	Cell-to-cell lactate shuttle operates in heart and is important in age-related heart failure. Aging, 2020, 12, 3388-3406.	1.4	18
232	Ability of the Activated PI3K/Akt Oncoproteins to Synergize with MEK1 and Induce Cell Cycle Progression and Abrogate the Cytokine-Dependence of Hematopoietic Cells. Cell Cycle, 2004, 3, 501-510.	1.3	17
233	OSU-03012 in the Treatment of Glioblastoma. Molecular Pharmacology, 2006, 70, 437-439.	1.0	17
234	Phospholipase C-Î²1 interacts with cyclin E in adipose- derived stem cells osteogenic differentiation. Advances in Biological Regulation, 2019, 71, 1-9.	1.4	17

#	Article	IF	Citations
235	GSK3 as a Regulator of Cytoskeleton Architecture: Consequences for Health and Disease. Cells, 2021, 10, 2092.	1.8	17
236	Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells. Oncotarget, 2017, 8, 76525-76557.	0.8	17
237	Exploiting p53 Status to Enhance Effectiveness of Chemotherapy by Lowering Associated Toxicity. Oncotarget, 2011, 2, 109-112.	0.8	17
238	A novel DAG-dependent mechanism links PKCa and Cyclin B1 regulating cell cycle progression. Oncotarget, 2014, 5, 11526-11540.	0.8	17
239	Development of a Conditional In vivo Model to Evaluate the Efficacy of Small Molecule Inhibitors for the Treatment of Raf-Transformed Hematopoietic Cells. Cancer Research, 2005, 65, 9962-9970.	0.4	16
240	Targeting the cancer initiating cell: The Achillesâ€™ heel of cancer. Advances in Enzyme Regulation, 2011, 51, 152-162.	2.9	16
241	miRNAs and their roles in KSHV pathogenesis. Virus Research, 2019, 266, 15-24.	1.1	16
242	Recent Progress in Discovering the Role of Carotenoids and Their Metabolites in Prostatic Physiology and Pathology with a Focus on Prostate Cancerâ€"A Reviewâ€"Part I: Molecular Mechanisms of Carotenoid Action. Antioxidants, 2021, 10, 585.	2.2	16
243	Location-dependent role of phospholipase C signaling in the brain: Physiology and pathology. Advances in Biological Regulation, 2021, 79, 100771.	1.4	16
244	Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia. Expert Opinion on Therapeutic Targets, 2013, 17, 921-936.	1.5	15
245	Diagnostic value of neutrophil gelatinase-associated lipocalin/matrix metalloproteinase-9 pathway in transitional cell carcinoma of the bladder. Tumor Biology, 2016, 37, 9855-9863.	0.8	15
246	Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines. Aging, 2020, 12, 10194-10210.	1.4	15
247	PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines. Oncotarget, 2017, 8, 23213-23227.	0.8	15
248	Raf-induced cell cycle progression in human TF-1 hematopoietic cells. Cell Cycle, 2002, 1, 220-6.	1.3	15
249	Saquinavir-NO-targeted S6 protein mediates sensitivity of androgen-dependent prostate cancer cells to TRAIL. Cell Cycle, 2012, 11, 1174-1182.	1.3	14
250	Comparative Study of Rapamycin and Temsirolimus Demonstrates Superimposable Antiâ€Tumour Potency on Prostate Cancer Cells. Basic and Clinical Pharmacology and Toxicology, 2013, 112, 63-69.	1.2	14
251	Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment. Advances in Biological Regulation, 2013, 53, 146-155.	1.4	14
252	Dimeric and tetrameric forms of muscle fructose-1,6-bisphosphatase play different roles in the cell. Oncotarget, 2017, 8, 115420-115433.	0.8	14

#	Article	IF	Citations
253	Subcellular Localization Relevance and Cancer-Associated Mechanisms of Diacylglycerol Kinases. International Journal of Molecular Sciences, 2020, 21, 5297.	1.8	14
254	GSK3 and miRNA in neural tissue: From brain development to neurodegenerative diseases. Biochimica Et Biophysica Acta - Molecular Cell Research, 2020, 1867, 118696.	1.9	14
255	Recent Progress in Discovering the Role of Carotenoids and Metabolites in Prostatic Physiology and Pathologyâ€"A Reviewâ€"Part II: Carotenoids in the Human Studies. Antioxidants, 2021, 10, 319.	2.2	14
256	Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia. Oncotarget, 2016, 7, 55690-55703.	0.8	14
257	Transformation of B and non-B cell lines with the 2,4,6- trinitrophenyl (TNP)-specific immunoglobulin genes. European Journal of Immunology, 1985, 15, 1117-1124.	1.6	13
258	Radiosensitization of prostate cancer by priming the wild-type p53-dependent cellular senescence pathway. Cancer Biology and Therapy, 2007, 6, 1176-1181.	1.5	13
259	Novel approaches to target cancer initiating cellsâ€"Eliminating the root of the cancer. Advances in Biological Regulation, 2012, 52, 249-264.	1.4	13
260	Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes. Expert Opinion on Therapeutic Targets, 2016, 20, 677-687.	1.5	13
261	Effects of Ectopic Expression of NGAL on Doxorubicin Sensitivity. Oncotarget, 2012, 3, 1236-1245.	0.8	13
262	Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression. Cells, 2022, 11, 2155.	1.8	13
263	Structure and expression of the T cell receptor gamma locus in pre-B and early hemopoietic cells. European Journal of Immunology, 1989, 19, 2303-2308.	1.6	12
264	Modulation of Raf/MEK/ERK kinase activity does not affect the chemoresistance profile of advanced prostate cancer cells. International Journal of Oncology, 2005, 26, 1637-44.	1.4	12
265	Effects of Endogenous Epidermal Growth Factor Receptor Signaling on DNA Synthesis and ERK Activation in a Cytokine-Dependent Hematopoietic Cell Line. Cell Cycle, 2005, 4, 818-821.	1.3	11
266	Activated EGFR Promotes the Survival of B-Lineage Acute Leukemia in the Absence of Stromal Cells. Cell Cycle, 2005, 4, 483-487.	1.3	11
267	Signaling Intermediates (PI3K/PTEN/AKT/mTOR and RAF/MEK/ERK Pathways) as Therapeutic Targets for Anti-Cancer and Anti-Angiogenesis Treatments. Current Signal Transduction Therapy, 2009, 4, 130-143.	0.3	11
268	Models of Anergy in the Human Jurkat T Cell Line. Assay and Drug Development Technologies, 2003, 1, 537-544.	0.6	10
269	Docetaxel Cytotoxicity is Enhanced by Inhibition of the Raf/MEK/ERK Signal Transduction Pathway. Cancer Biology and Therapy, 2003, 2, 676-677.	1.5	10
270	B-Raf and Insulin Synergistically Prevent Apoptosis and Induce Cell Cycle Progression in Hematopoietic Cell. Cell Cycle, 2004, 3, 184-191.	1.3	10

#	Article	IF	Citations
271	Inhibition of CREB transcriptional activity in human T lymphocytes by oxidative stress. Free Radical Biology and Medicine, 2005, 38, 1653-1661.	1.3	10
272	Biology of Kaposi's sarcoma-associated herpesvirus. Frontiers in Bioscience - Landmark, 2005, 10, 2882.	3.0	10
273	Induction of caspase-independent apoptotic-like cell death of mouse mammary tumor TA3Ha cells in vitro and reduction of their lethality in vivo by the novel chemotherapeutic agent GIT-27NO. Free Radical Biology and Medicine, 2010, 48, 1090-1099.	1.3	10
274	Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals. Advances in Biological Regulation, 2019, 72, 22-40.	1.4	10
275	GSK-3 and miRs: Master regulators of therapeutic sensitivity of cancer cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2020, 1867, 118770.	1.9	10
276	GSK-3-associated signaling is crucial to virus infection of cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2020, 1867, 118767.	1.9	10
277	Insulin/IGF1-PI3K-dependent nucleolar localization of a glycolytic enzyme - phosphoglycerate mutase 2, is necessary for proper structure of nucleolus and RNA synthesis. Oncotarget, 2015, 6, 17237-17250.	0.8	10
278	Synergistic Proapoptotic Activity of Recombinant TRAIL Plus the Akt Inhibitor Perifosine in Acute Myelogenous Leukemia Cells-a Novel Therapeutic Approach for Leukemia Displaying Elevated Akt Signaling.. Blood, 2008, 112, 957-957.	0.6	10
279	GSK-3 in liver diseases: Friend or foe?. Biochimica Et Biophysica Acta - Molecular Cell Research, 2020, 1867, 118743.	1.9	10
280	Cigarette smoke concentrate inhibits Kaposi's sarcoma-associated herpesvirus infection. Virus Research, 2005, 114, 172-176.	1.1	9
281	The cyclin-dependent kinase inhibitor roscovitine and the nucleoside analog sangivamycin induce apoptosis in caspase-3 deficient breast cancer cells independent of caspase mediated P-glycoprotein cleavage: Implications for therapy of drug resistant breast cancers. Cell Cycle, 2009, 8, 1421-1425.	1.3	9
282	Nuclear PI-PLCÎ²1 and Myelodysplastic Syndromes: Genetics and Epigenetics. Current Pharmaceutical Design, 2012, 18, 1751-1754.	0.9	9
283	GSK-3 signaling in health. Advances in Biological Regulation, 2017, 65, 1-4.	1.4	9
284	Antitumor Mechanism of the Essential Oils from Two Succulent Plants in Multidrug Resistance Leukemia Cell. Pharmaceuticals, 2019, 12, 124.	1.7	9
285	Abilities of Î²-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cells. Advances in Biological Regulation, 2020, 75, 100672.	1.4	9
286	The NUPR1/p73 axis contributes to sorafenib resistance in hepatocellular carcinoma. Cancer Letters, 2021, 519, 250-262.	3.2	9
287	Modulation of Raf/MEK/ERK kinase activity does not affect the chemoresistance profile of advanced prostate cancer cells. International Journal of Oncology, 2005, 26, 1637.	1.4	8
288	GSK-3Î² is a critical mediator of tetrandrine induced cell cycle arrest and cytotoxicity. Cancer Biology and Therapy, 2008, 7, 1079-1079.	1.5	8

#	Article	IF	Citations
289	Where are we with understanding of COVID-19?. Advances in Biological Regulation, 2020, 78, 100738.	1.4	8
290	Drug-resistance in doxorubicin-resistant FL5.12 hematopoietic cells: elevated MDR1, drug efflux and side-population positive and decreased BCL2-family member expression. Oncotarget, 2017, 8, 113013-113033.	0.8	8
291	B-raf and insulin synergistically prevent apoptosis and induce cell cycle progression in hematopoietic cells. Cell Cycle, 2004, 3, 189-96.	1.3	8
292	Phytol and Heptacosane Are Possible Tools to Overcome Multidrug Resistance in an In Vitro Model of Acute Myeloid Leukemia. Pharmaceuticals, 2022, 15, 356.	1.7	8
293	Recent advances in MDS mutation landscape: Splicing and signalling. Advances in Biological Regulation, 2020, 75, 100673.	1.4	7
294	Quantitative phosphoproteome analysis of embryonic stem cell differentiation toward blood. Oncotarget, 2015, 6, 10924-10939.	0.8	7
295	Pharmacological breast cancer therapy (review). International Journal of Oncology, 2005, 27, 1341-4.	1.4	7
296	Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53. Advances in Biological Regulation, 2021, 79, 100780.	1.4	6
297	Activation of Nonexpressed Endogenous Ecotropic Murine Leukemia Virus by Transfection of Genomic DNA into Embryo Cells. Journal of Virology, 1983, 45, 950-955.	1.5	6
298	Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53. Cells, 2022, 11, 794.	1.8	6
299	Inositide-Dependent Nuclear Signalling in Health and Disease. Handbook of Experimental Pharmacology, 2019, 259, 291-308.	0.9	5
300	Where are we with understanding of COVID-19?. Advances in Biological Regulation, 2020, 77, 100745.	1.4	5
301	Phospholipase C beta1 (PIâ€PLCbeta1)/Cyclin D3/protein kinase C (PKC) alpha signaling modulation during ironâ€induced oxidative stress in myelodysplastic syndromes (MDS). FASEB Journal, 2020, 34, 15400-15416.	0.2	5
302	Role of PLCÎ³1 in the modulation of cell migration and cell invasion in glioblastoma. Advances in Biological Regulation, 2022, 83, 100838.	1.4	5
303	Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties. Aging, 2022, 14, 3365-3386.	1.4	5
304	Pathobiology and Therapeutic Relevance of GSK-3 in Chronic Hematological Malignancies. Cells, 2022, 11, 1812.	1.8	5
305	Enhancing the effectiveness of nucleoside analogs with mTORC1 blockers to treat acute myeloid leukemia patients. Cell Cycle, 2013, 12, 1815-1816.	1.3	4
306	Foreword: â€œTargeting signaling pathways in stem cellsâ€• Advances in Biological Regulation, 2014, 56, 1-5.	1.4	4

#	Article	IF	Citations
307	Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53. Advances in Biological Regulation, 2021, , 100840.	1.4	4
308	APR-246â€"The Mutant TP53 Reactivatorâ€"Increases the Effectiveness of Berberine and Modified Berberines to Inhibit the Proliferation of Pancreatic Cancer Cells. Biomolecules, 2022, 12, 276.	1.8	4
309	Microarray and pathway analysis reveals decreased CDC25A and increased CDC42 associated with slow growth of Bcl-2-over-expressing immortalized breast cell line. Cell Cycle, 2008, 7, 3062-3073.	1.3	3
310	Combining chemo-, hormonal and targeted therapies to treat breast cancer (Review). Molecular Medicine Reports, 0, , .	1.1	3
311	The involvement of CaM-KII in insulin induced cell proliferation. Cell Cycle, 2009, 8, 1979-1983.	1.3	3
312	Lamin B1 Accumulationâ€™s Effects on Autosomal Dominant Leukodystrophy (ADLD): Induction of Reactivity in the Astrocytes. Cells, 2021, 10, 2566.	1.8	3
313	Enhanced ability of the progenipoietin-1 to suppress apoptosis in human hematopoietic cells. International Journal of Molecular Medicine, 2002, 10, 385.	1.8	2
314	Critical Roles of the Raf/MEK/ERK Pathway in Apoptosis and Drug Resistance. , 2006, , 101-134.		2
315	New Perspectives in HCV Therapy: Entry Inhibitors. Recent Patents on Anti-infective Drug Discovery, 2010, 5, 181-194.	0.5	2
316	No-Modified Saquinavir is Equally Efficient Against Doxorubicin Sensitive and Resistant Non-Small Cell Lung Carcinoma Cells / MODIFIKOVANA KOVANA FORMA SAKVINAVIRA EFIKASNO SU PRIMI RA RAST Ä†ELIJA NESITNOÄ†ELIJSKOG KARCINOMA PLUÄ†A RAZLIÄŒITE OSETUIVOSTI NA DOKSORUBICIN. Journal of Medical Biochemistry, 2013, 32, 406-416.	0.7	2
317	Targeting Survival Cascades Induced by Activation of Ras/Raf/MEK/ERK and PI3K/Akt Pathways to Sensitize Cancer Cells to Therapy. , 2008, , 81-114.		2
318	Role for Raf in the entry of viruses associated with AIDS (Review). International Journal of Oncology, 2004, 25, 469.	1.4	1
319	New Agents and Approaches for Targeting the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR Cell Survival Pathways. , 2013, , 331-372.		1
320	Current therapy and new drugs: a road to personalized treatment of myelodysplastic syndromes. Expert Review of Precision Medicine and Drug Development, 2018, 3, 23-31.	0.4	1
321	Comparative Gene Profiling of Acute Myeloid Leukemia (AML) and Malignant Melanoma (MEL) Cell Lines Exposed to the MEK Inhibitor PD0325901 Reveals Common Effectors of the MEK/ERK Kinase Module.. Blood, 2007, 110, 3470-3470.	0.6	1
322	PI-103, a Dual Inhibitor of Class IA Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin, Has Cytotoxic Activity in T-Cell Acute Lymphoblastic Leukemia Cells: A New Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia.. Blood, 2008, 112, 1921-1921.	0.6	1
323	Dominant Role of Raf/MEK/ERK Signaling in Hematopoietic Cell Cycle Progression, Prevention of Apoptosis and Drug Resistance.. Blood, 2006, 108, 1116-1116.	0.6	1
324	The AKT Inhibitor, A443654, Induces Cell Cycle Arrest, Apoptosis and Synergizes with Chemotherapeutic Drugs in Multi-Drug Resistant T-Cell Acute Lymphoblastic Leukemia - A Novel Agent for Therapy of Drug Resistant ALL.. Blood, 2007, 110, 3344-3344.	0.6	1

#	Article	IF	Citations
325	Development of Mek inhibition (MEK-I)-Based Therapeutic Strategies in Acute Myeloid Leukemia (AML). Blood, 2008, 112, 860-860.	0.6	1
326	Rationale for Targeting of YY1 in Drug-resistant Leukemias. Forum on Immunopathological Diseases and Therapeutics, 2010, 1, 65-79.	0.1	1
327	From Targets to Targeted Therapies in Hepatocellular Carcinoma. Forum on Immunopathological Diseases and Therapeutics, 2014, 5, 145-194.	0.1	1
328	Fibroblastic, Hematopoietic, and Hormone Responsive Epithelial Cell Lines and Culture Conditions for Elucidation of Signal Transduction and Drug Resistance Pathways by Gene Transfer. , 2003, 218, 185-202.		0
329	Elucidation of Signal Transduction Pathways by Transfection of Cells with Modified Oncogenes. , 2003, 218, 203-220.		0
330	A New Hope for Treatment of Glioblastomas. Cancer Biology and Therapy, 2003, 2, 354-355.	1.5	0
331	Upping the bid on engineered inducible cell death.. Cancer Biology and Therapy, 2005, 4, 537-537.	1.5	0
332	Raf/MEK/ERK Signaling. , 2015, , 275-305.		0
333	Foreword for the special issue advances in COVID-19: Biology and clinic. Advances in Biological Regulation, 2020, 77, 100744.	1.4	0
334	A Novel Ring-Substituted Diindolylmethane 1,1-bis [3â€²-(5-methoxyindolyl)]-1-(p-t-butylphenyl) Methane Abrogates ERK Activation and Induces Apoptosis in Acute Myeloid Leukemia (AML).. Blood, 2004, 104, 3399-3399.	0.6	0
335	Key Roles of the Raf-1 and Akt in Drug Resistance, Cell Cycle Progression and the Prevention of Apoptosis in Hematopoietic Cells.. Blood, 2005, 106, 1356-1356.	0.6	0
336	Role of BRAF Mutations in Hematopoietic Malignancies and the Induction of Cytokine-Independence-Synergy with PI3K/Akt Pathway.. Blood, 2005, 106, 4291-4291.	0.6	0
337	Mutations of the Catalytic Subunit of Class IA PI3K Are Constitutively Active and Confer Factor-Independent Growth to Early Hematopoietic Cells.. Blood, 2006, 108, 1455-1455.	0.6	0
338	The Novel Akt Inhibitor Perifosine Induces Apoptosis, Cell Cycle Arrest and Synergizes with Chemotherapeutic Drugs in Acute Myelogenous Leukemia Cells by a JNK Dependent Mechanism - A Novel Therapeutic Approach for Leukemia Displaying Elevated Akt Signaling.. Blood, 2007, 110, 3355-3355.	0.6	0
339	Roles of Raf/MEK/ERK and PI3K/Akt/mTOR Pathways in Prevention of Apoptosis and Induction of Drug Resistance in Myeloid Hematopoietic Cells.. Blood, 2007, 110, 641-641.	0.6	0
340	Mutations in the Catalytic Subunit of Class IA PI3K Are Leukemogenic In Vivo.. Blood, 2007, 110, 875-875.	0.6	0
341	Roles of Raf/MEK/ERK and PI3K/Akt/mTOR Signaling and p53 Pathways on Apoptosis, Drug Resistance and Therapeutic Sensitivity of Early Hematopoietic Precursor Cells. Blood, 2008, 112, 503-503.	0.6	0
342	The Glycogensynthase Kinase 3b (GSK-3Î²) Is Involved in Leukemic Transformation. Blood, 2008, 112, 4489-4489.	0.6	0

#	Article	IF	Citations
343	Erucylphosphohomocholine, the First Intravenously Applicable Alkylphosphocholine, Induces Cell Cycle Arrest, Apoptosis, and Synergizes with Chemotherapeutic Drugs in Acute Myelogenous Leukemia Cells-a Novel Therapeutic Approach for Leukemia.. Blood, 2008, 112, 1330-1330.	0.6	0
344	Parallel Signaling through PI3K/AKT/mTOR Mediates Resistance to MEK Inhibition in Preclinical Models of Acute Myeloid Leukemia (AML): Synergistic Effects of Combined MEK and mTOR Inhibition.. Blood, 2009, 114, 594-594.	0.6	0
345	Simultaneous Targeting of Bcl-2/Bcl-Xl and MEK/ERK Results in Highly Synergistic Induction of Apoptosis in Human AML, Both in Vitro and In Vivo.. Blood, 2009, 114, 2757-2757.	0.6	0
346	Dual Inhibition of Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin with NVP-BEZ235 as a New Therapeutic Option for T-Cell Acute Lymphoblastic Leukemia.. Blood, 2009, 114, 2025-2025.	0.6	0
347	COMMENTARY. Regulation of Drug and Immune Resistance by YY1 in Cancer. Forum on Immunopathological Diseases and Therapeutics, 2010, 1, 149-151.	0.1	0